In a major fillip to India’s fast-growing diagnostics landscape, Bengaluru-based healthtech startup OrangeHealth announced its expansion into 10 new cities, days after closing a fresh funding round of $25 million. The company, known for its rapid, on-demand diagnostic testing services, is looking to change the ballgame of how Indians access healthcare through its signature 60-minute sample collection and faster report turnaround times.
This new capital is also led by marquee global investors at an opportune time when India’s diagnostic services market is standing at an inflection point, with trends shifting toward home-based testing, convenience-driven models, and digitally integrated care solutions. Accelerated growth at OrangeHealth underlines increasing demand for technology-enabled health services, led by urban consumers who are looking for speed, accuracy, and reliability.
A dream of building India’s fastest diagnostics network.
Founded by Dhruv Gupta and Uttam Kumar, OrangeHealth was launched with a vision to create the most efficient diagnostics experience in the country. The startup felt right from the beginning that the existing model, where patients are forced to travel to labs or wait for hours for technicians, is already obsolete and an inconvenient one.
The biggest differentiator for OrangeHealth is their promise of “samples collected in 60 minutes”, which is powered by a sophisticated logistics engine, real-time phlebotomist allocation, and partnerships with top NABL-accredited labs. This operational model has helped the startup build trust among patients, doctors, and corporate health partners alike.
This expansion will now see OrangeHealth expand its care into key metros and fast-growing Tier-1 cities like Chennai, Kolkata, Ahmedabad, Pune, Jaipur, Chandigarh, Indore, Lucknow, Surat, and Coimbatore. These cities reflect a strong trend of digital adoption for health services along with growing demand for rapid testing solutions.
Funding Drives Aggressive Expansion
This infusion of $25 million marks one of the largest funding rounds in recent times in the diagnostics-tech segment. Investors are increasingly optimistic about the digital-health opportunity in India, with growing awareness about healthcare, lifestyle diseases, preventive care culture, and demand for convenience-first services.
OrangeHealth will deploy the newly raised capital for:
While still growing a citywide fleet of phlebotomists
Establish micro-logistics hubs in advance for faster delivery.
Enhancing partnerships with diagnostic laboratories
Developing tracking and reporting systems driven by AI.
Introducing new specialised test offerings and packages.
For instance, according to estimates by various industry analysts, exponential growth is expected in home diagnostics within the next five years, with players like OrangeHealth positioned to lead through speed and tech innovation.
Competing in a Crowded Healthtech Landscape
The diagnostics ecosystem in India has witnessed aggressive competition from established players like Dr Lal PathLabs, Thyrocare, and Apollo Diagnostics to newer digital-first entrants like PharmEasy and Healthians. In spite of that, OrangeHealth has created a niche for itself.
A commitment to fast turnaround and a customer experience led by technology has allowed it to differentiate in an otherwise fragmented market dominated by slower, legacy processes. The seamless booking system on the platform, real-time tracking, and instant digital report delivery ring especially true among the urban millennial and Gen-Z demography.
OrangeHealth growth has been matched by clinical quality in that process. It hasn’t built its own labs but has decided to partner with certified third-party diagnostic companies in order to provide credible results while its internal resources focus on logistics and patient experience.
Improving Healthcare Accessibility
One of the long-term objectives of OrangeHealth is to enhance access to quality diagnostics beyond metro cities. Large parts of India still have to rely on inadequate or untimely testing services, which is one of the major reasons for delays in diagnosis.
By expanding into Tier-1 and Tier-2 markets, OrangeHealth aims to bridge this critical gap. Rising awareness about healthcare post-pandemic has, in turn, increased demand for at-home tests for blood work, metabolic panels, hormone analysis, allergy panels, and preventive health screenings.
The company is also working on partnerships with hospitals, insurance companies, and corporate wellness programmes to develop integrated health-management experiences.
The Road Ahead
The expansion of OrangeHealth signals a sea change in India’s healthcare infrastructure – from traditional lab visits to technology-powered doorstep diagnostics. Expanding the test menu to include advanced diagnostics on genetic testing, chronic disease monitoring, and AI-driven health insights are other areas the company is focusing on as it scales. Strong investor backing, coupled with robust demand and a scalable operational model, places OrangeHealth in a very good position to shape the future of India’s diagnostics sector. The next few years will likely tell if the platform can scale up to become a national leader and change how millions of Indians access medical testing.
